论文部分内容阅读
目的:观察阿替普酶联合丁苯酞治疗急性缺血性脑卒中的临床疗效和安全性.方法:急性缺血性脑卒中患者108例随机分为观察组和对照组各54例.两组均给予控制血糖、血脂、血压等常规治疗,在此基础上对照组给予阿替普酶溶栓治疗,观察组在对照组基础上再加用丁苯酞氯化钠注射液治疗.疗程均为14 d.比较两组的临床疗效、美国国立卫生院卒中量表(NIHSS)评分、日常生活能力得分及药品不良反应发生情况.结果:观察组治疗总有效率为94.4%,明显高于对照组的81.5%(P<0.05).治疗7 d,14 d后,两组NIHSS评分均较前明显降低(P<0.05),生活能力Barthel指数得分则较前明显升高(P<0.05);且观察组两项评分均优于对照组同时点(P0.05).结论:阿替普酶联合丁苯酞治疗急性缺血性脑卒中,能有效改善患者的神经功能,提高日常生活能力,安全有效,值得临床推广.“,”Objective:To observe the clinical efficacy and safety of alteplase combined with butylphthalide in the patients with a-cute ischemic stroke. Methods:Totally 108 cases of acute ischemic stroke patients in our hospital were selected and randomly divided into the experimental group and the control group with 54 ones in each. The two groups were both given such treatments as blood sugar control, blood lipid control, blood pressure control and the other conventional treatment, and the control group was given alteplase for thrombolysis treatment additionally, while the experimental group was given butylphthalide sodium chloride injection combined with al-teplase additionally. Both groups were treated for 14 days. The clinical effect, NIHSS score, daily life ability score and the adverse re-actions in the two groups were observed and compared. Results: The total effective rate in the experimental group was 94. 4%, and that was 81. 5% in the control group, and the difference was statistically significant (P<0. 05). The NIHSS score was reduced signifi-cantly(P<0. 05),and the life ability based on Barthel index score increased significantly (P<0. 05) in the two group after the 7-and 14-day treatment,and the improvement of the experimental group was significantly better than that of the control group with statistically significant differences (P 0.05). Conclusion: In the treatment of acute ischemic stroke, alteplase combined with bu-tylphthalide is safe and effective, and can effectively improve the neurological function and the ability of daily life, which is worthy of clinical application.